Tag: nerves

IRVINE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- iHerb, a globally renowned health and wellness e-commerce platform, which has been established for 29 years, recently launched its 618 Peak Shopping Festival (June 11-20) and offered a month-long discount program to give back to users in Hong Kong and Southeast Asia. The platform insists on direct sourcing from brands and self-operated warehouse delivery to ensure that products are genuine. It currently covers 185 countries and regions, with over 11 million active users, and its products include nearly 3,000 brands and over 50,000 premium items in areas such as dietary nutrition, sports and health, and beauty and personal care.

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins
- Series B round in planning to support pivotal U.S. trial
- New CEO appointment signals next phase of growth and expansion